Q2 2026 Codexis Inc Earnings Call Transcript
Key Points
- Codexis Inc (CDXS) reported solid Q2 2026 revenue of $14.9 million, with a significant improvement in its biocatalytic enzyme business, signaling a return to growth.
- Product gross margin improved to 73% in Q2 2026, driven by higher sales of more profitable products, and the company now expects full-year gross margins to improve to the high 60s%.
- The ECO Synthesis platform demonstrated new capabilities at TIDES-US, including precise control of phosphorothioate stereochemistry and starterless synthesis, which have generated significant customer interest and advanced commercial discussions.
- The company successfully raised approximately $25 million in net proceeds from an equity financing, extending its cash runway through 2028 and providing greater financial stability.
- The pharma biocatalysis business remains stable and profitable, with 14 commercial products supported, including four new product approvals in 2026, and a robust pipeline of 15 programs in Phase 2/3 clinical development.
- Construction of the GMP manufacturing facility is on track, with equipment ordered and a building permit application imminent, positioning the company to support customer IND filings and clinical trials.
- Total revenues for Q2 2026 were $14.9 million, a slight decrease from $15.3 million in the same period last year, indicating a modest year-over-year decline.
- The company continues to incur net losses, reporting a net loss of $12 million in Q2 2026, though this is an improvement from the $13.3 million loss in Q2 2025.
- Cash and short-term investments decreased to $54.9 million at the end of Q2 2026 from $78.2 million at the end of 2025, reflecting significant cash burn.
- The revenue guidance for 2026 remains unchanged at $72 million to $76 million, with a heavy weighting toward the second half, implying a significant step-up in revenue that may be challenging to achieve.
- The biocatalysis business is subject to lumpy and unpredictable order patterns from customers, which can create volatility in quarterly revenue performance.
- The ECO Synthesis technology is still in the R&D stage for some capabilities, such as starterless synthesis, and the company faces technical hurdles in scaling up to kilogram-scale production, which may delay commercialization.
Greetings and welcome to the Codexis second-quarter 2026 financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce Georgia Erbez, Chief Financial Officer and Chief Business Officer. Thank you. You may begin.
Thank you, operator. With me today are Alison Moore, President and Chief Executive Officer; Stefan Lutz, Chief Scientific Officer; and Britton Jimenez, Senior Vice President, Sales and Marketing.
During this call, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2026 revenue, anticipated milestones in product launches, facility expansions, technical milestones, and public announcements related thereto, as well as our strategies and prospects for revenue growth, paths to profitability, and successful execution of current and future programs and partnerships.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
